Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer

Summary

RATIONALE: Vaccines made from tumor cells or dendritic cells may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is more effective in treating patients with prostate cancer. PURPOSE: This phase II trial is studying how well the combination of a proven effective allogenic whole prostate carcinoma cell (APCC) vaccine co-administered with ex vivo generated dendritic cells (DCs)(DC-APCC) extend the time to prostate cancer progression.

Timeline

Start

2009-01

Primary completion

2009-12

Completion

2010-03

Drugs

Indications